
Promising Alzheimer Antibody-Based Immunotherapy
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.